๐ŸŒ EnglishEN

AI Cure is a research tool showing open data. Not medical advice. Discuss with your doctor. Terms

๐Ÿงช

Trial Match

Clinical trials test new treatments โ€” sometimes the newest options available for a disease. Find trials that are recruiting now, near you. Open one to see its eligibility rules as simple questions to go through with your doctor.

Know your stage or your test results (such as EGFR, HER2 or BRCA)? Match trials to your own profile - nothing you type is saved.

๐ŸŽฏ Match trials to me

30 recruiting trials

for Recurrent B Acute Lymphoblastic Leukemia

CD19x22 Chimeric Antigen Receptor T-cell Therapy (CAR T) in Pediatric B-ALL NCT06559189Phase 11 site๐Ÿ“ Aurora University of Colorado, Denver ยท Tests: CD19x22 CAR T Phase Ib/II Study Assessing the Clinical Activity and Safety of Brexucabtagene Autoleucel as a Consolidation in Patients With Relapsed/Refractory (R/R) and Newly Diagnosed B-cell Acute Lymphocytic Leukemia (ALL) Post Cytoreduction With Mini-HCVD-inotuzumab-blinatumomab/HCVAD-inotuzumab-blinatumomab NCT06287229Phase 1, Phase 21 site๐Ÿ“ Houston M.D. Anderson Cancer Center ยท Tests: Blinatumomab, Inotuzumab Ozogamicin, Hyper-CVAD, Mini-hyper-CVD A Study of CD19 Targeted CAR T Cell Therapy in Pediatric Patients With Relapsed or Refractory B Cell Acute Lymphoblastic Leukemia (B ALL) and Aggressive Mature B-cell Non-Hodgkin Lymphoma (B NHL) NCT06173518Phase 114 sites๐Ÿ“ Los Angeles๐Ÿ“ Palo Alto๐Ÿ“ Aurora Autolus Limited ยท Tests: AUTO1 Pomalidomide After CAR T-cell Therapy for the Treatment of Relapsed or Refractory CD19+ B-cell Leukemia or Lymphoma NCT07532525Phase 11 site๐Ÿ“ Ann Arbor University of Michigan Rogel Cancer Center ยท Tests: Biospecimen Collection, Pomalidomide Tissue, Blood, and Body Fluid Sample Collection From Patients With Hematologic Cancer NCT01137643n/a1 site๐Ÿ“ Chapel Hill UNC Lineberger Comprehensive Cancer Center ยท Tests: biologic sample preservation procedure, cytology specimen collection procedure UCD19 CarT in Treatment of Pediatric B-ALL and B-NHL NCT04544592Phase 1, Phase 21 site๐Ÿ“ Aurora University of Colorado, Denver ยท Tests: CD19CAR-CD3Zeta-4-1BB-Expressing Autologous T-Lymphocyte Cells Combination Chemotherapy in Treating Patients With Relapsed or Refractory Acute Lymphoblastic Leukemia, Lymphoblastic Lymphoma, Burkitt Lymphoma/Leukemia, or Double-Hit Lymphoma/Leukemia NCT03136146Phase 21 site๐Ÿ“ Houston M.D. Anderson Cancer Center ยท Tests: Bortezomib, Clofarabine, Cyclophosphamide, Dexamethasone, Etoposide CAV Regimen for R/R Ph- B-ALL NCT05657652NA1 site๐Ÿ“ Suzhou The First Affiliated Hospital of Soochow University ยท Tests: cladribine, cytarabine,venetoclax Adaptive Dual-Target CAR-T Cells for Relapsed or Refractory Hematologic Malignancies NCT07523555Phase 1, Phase 21 site๐Ÿ“ Shenzhen Beijing Biotech ยท Tests: Autologous CD19/CD22 dual-target CAR-T module, Autologous CD19/CD20 dual-target CAR-T module, Autologous BCMA/CD19 dualโ€ฆ Personalized NK Cell Therapy in CBT NCT02727803Phase 21 site๐Ÿ“ Houston M.D. Anderson Cancer Center ยท Tests: Allogeneic Natural Killer Cell Line NK-92, Anti-Thymocyte Globulin, Busulfan, Clofarabine, Cyclophosphamide HEM iSMART-D: Trametinib + Dexamethasone + Chemotherapy in Children With Relapsed or Refractory Hematological Malignancies NCT05658640Phase 1, Phase 236 sites๐Ÿ“ Vienna๐Ÿ“ Ghent๐Ÿ“ Copenhagen Princess Maxima Center for Pediatric Oncology ยท Tests: Trametinib, Dexamethasone, Cyclophosphamide, Cytarabine, Intrathecal chemotherapy HEM-iSMART-B: Dasatinib + Venetoclax + Dexamethasone + Cyclophosphamide and Cytarabine in Pediatric Patients With Relapsed or Refractory Hematological Malignancies NCT05751044Phase 1, Phase 233 sites๐Ÿ“ Vienna๐Ÿ“ Ghent๐Ÿ“ Copenhagen Princess Maxima Center for Pediatric Oncology ยท Tests: Dasatinib, Venetoclax, Dexamethasone, Cyclophosphamide, Cytarabine Tafasitamab (MOR00208) in Pediatric Patients With Relapsed or Refractory Acute B Lineage Leukemia NCT05366218Phase 1, Phase 211 sites๐Ÿ“ Freiburg im Breisgau๐Ÿ“ Tรผbingen๐Ÿ“ Ulm University Hospital Tuebingen ยท Tests: Tafasitamab Safety and Efficacy of CAR T Cell Therapy in Patients with R/r B-ALL NCT06635330Phase 1, Phase 21 site๐Ÿ“ Tehran Kara Yakhteh Tajhiz Azma Company ยท Tests: anti-CD19 CAR T cell therapy CD19-targeted CAR T Cell Autotransfusion for the Treatment of Recurrent/Refractory B-cell Acute Lymphoblastic Leukemia/Lymphoblastic Lymphoma in Children With CD19+ NCT06355739NA2 sites๐Ÿ“ Tianjin๐Ÿ“ Tianjin Zhu Xiaofan ยท Tests: CAR T cell injection CART19 Cells Effects in Patients with Relapsed or Refractory Acute Lymphoblastic Leukemia and Non-Hodgkin's Lymphoma NCT05054257Phase 11 site๐Ÿ“ Prague Institute of Hematology and Blood Transfusion, Czech Republโ€ฆ ยท Tests: Autologous CAR19 T lymphocytes CD45RA-depleted CD19-CAR T Cell Consolidation After TCRฮฑฮฒ+/CD19 B Cell-depleted Haploidentical Hematopoietic Cell Transplantation for Relapsed/Refractory CD19+ ALL and Lymphoma NCT07257419Phase 11 site๐Ÿ“ Memphis St. Jude Children's Research Hospital ยท Tests: Anti-Thymocyte Globulin (Rabbit), Cyclophosphamide, Fludarabine, Thiotepa, Mesna NexCAR19 (Talikabtagene Autoleucel) in Relapsed/Refractory B-Cell Malignancies (NexCAR19) NCT07502118Phase 2, Phase 34 sites๐Ÿ“ Ankara๐Ÿ“ Ankara๐Ÿ“ Ankara Health Institutes of Turkey ยท Tests: Talikabtagene Autoleucel Study of Out of Specification for Tisagenlecleucel NCT04094311Phase 355 sites๐Ÿ“ Hamilton๐Ÿ“ Ottawa๐Ÿ“ Toronto Novartis Pharmaceuticals ยท Tests: CTL019 Phase 1/2 Study of UCART22 in Patients With Relapsed or Refractory CD22+ B-cell Acute Lymphoblastic Leukemia (BALLI-01) NCT04150497Phase 1, Phase 219 sites๐Ÿ“ Los Angeles๐Ÿ“ Aurora๐Ÿ“ Denver Cellectis S.A. ยท Tests: UCART22, CLLS52 Inotuzumab Ozogamicin and Combination Chemotherapy in Treating Patients With Acute Lymphoblastic Leukemia NCT01371630Phase 1, Phase 21 site๐Ÿ“ Houston M.D. Anderson Cancer Center ยท Tests: Blinatumomab, Cyclophosphamide, Cytarabine, Dexamethasone, Inotuzumab Ozogamicin Phase Ib Clinical Study of Keynatinib NCT04807881Phase 14 sites๐Ÿ“ Beijing๐Ÿ“ Beijing๐Ÿ“ Shanghai Medolution Ltd. ยท Tests: Keynatinib Registry of Older Patients With Cancer NCT01137825n/a7 sites๐Ÿ“ Boone๐Ÿ“ Chapel Hill๐Ÿ“ Greenville UNC Lineberger Comprehensive Cancer Center CD19-Directed Chimeric Antigen Receptor (CAR) T-Cell Therapy for Relapsed/Refractory B-Lineage Leukaemia / Lymphoma - A Feasibility Protocol NCT05648019Phase 22 sites๐Ÿ“ Singapore๐Ÿ“ Singapore KK Women's and Children's Hospital ยท Tests: Anti-CD19 CAR T-cells Genetically Engineered Cells (Anti-CD19/CD20/CD22 CAR T-cells) for the Treatment of Relapsed or Refractory Lymphoid Malignancies NCT05418088Phase 12 sites๐Ÿ“ Columbus๐Ÿ“ Columbus Sumithira Vasu ยท Tests: Anti-CD19/CD20/CD22 CAR T-Cells, Cyclophosphamide, Fludarabine Phosphate, Echocardiography, Multigated Acquisition Scan CD19-CD22-Bispecific Chimeric Antigen Receptor (CAR) T Cell Therapy for Pediatric Patients With Acute Lymphoblastic Leukemia NCT06777979Phase 11 site๐Ÿ“ Memphis St. Jude Children's Research Hospital ยท Tests: Fludarabine, Cyclophosphamide, Mesna, CD19-CD22 CAR T cell infusion Activated T-Cells Expressing 2nd or 3rd Generation CD19-Specific CAR, Advanced B-Cell NHL, ALL, and CLL (SAGAN) NCT01853631Phase 12 sites๐Ÿ“ Houston๐Ÿ“ Houston Baylor College of Medicine ยท Tests: Dose Escalation Phase:CD19.CAR/28 and CD19.CAR/28137 T cells, Expansion Phase: CD19.CAR/28 and CD19.CAR/28137 T cells A Clinical Study to Evaluate the Safety, Tolerability, and Preliminary Efficacy of B019 Injection in Subjects With Relapsed or Refractory B-cell Acute Lymphoblastic Leukemia. NCT06927466Phase 18 sites๐Ÿ“ Beijing๐Ÿ“ Nanchang๐Ÿ“ Nanchang Shanghai Pharmaceutical Group Biological Therapy Technologyโ€ฆ ยท Tests: B019 HEM-iSMART-C: Ruxolitinib + Venetoclax + Dexamethasone + Cyclophosphamide and Cytarabine in Pediatric Patients With Relapsed or Refractory Hematological Malignancies NCT05745714Phase 1, Phase 233 sites๐Ÿ“ Vienna๐Ÿ“ Ghent๐Ÿ“ Copenhagen Princess Maxima Center for Pediatric Oncology ยท Tests: Ruxolitinib, Venetoclax, Dexamethasone, Cyclophosphamide, Cytarabine Study of Oral Administration of LP-118 in Patients With Relapsed or Refractory CLL, SLL, MDS, MDS/MPN, AML, CMML-2, MPN-BP, ALL, MF, NHL, RT, MM or T-PLL. NCT04771572Phase 18 sites๐Ÿ“ Chicago๐Ÿ“ Boston๐Ÿ“ Chapel Hill Newave Pharmaceutical Inc ยท Tests: LP-118
๐Ÿ›ก๏ธ

AI Cure shows public evidence (Open Targets, ClinicalTrials.gov, PubMed, openFDA, DepMap, AlphaFold) with its source, and AI summaries that cite it โ€” not medical advice and not a cure. Treatment decisions belong with your doctor. Research ideas are shared only with approved researchers and labs, who can test them. In an emergency call your local emergency number (112 in India and Europe, 911 in the US). AI Cure Terms of Use ยท Privacy